课题基金 / 基金详情

Discovering the minimal optimal antipsychotic dose in patients with late-life schizophrenia – an open-label prospective [11C]-Raclopride Positron Emission Tomography study

Discovering the minimal optimal antipsychotic dose in patients with late-life schizophrenia – an open-label prospective [11C]-Raclopride Positron Emission Tomography study
发现晚年精神分裂症患者的最小最佳抗精神病药物剂量 — 一项开放标签前瞻性 [11C]-雷氯必利正电子发射断层扫描研究
批准号：
331488
负责人：
Chung Jun Ku
金额：
$1.27万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2014
资助国家：
加拿大
项目状态：
已结题
起止时间：
2014-12-01 至 2015-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=331488&lang=en
关键词：
Antipsychotic Dose Reduction Antipsychotic-Induced Side Effects Antipsychotics Dopamine D2/D3 Receptors Geriatrics Late-Life Schizophrenia Positron Emission Tomography Relapse Prevention

项目摘要

项目成果

Chung Jun Ku的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Schizophrenia (SCZ) is a debilitating illness with prevalence of 1% in global population. Patients with SCZ must receive a lifelong treatment by antipsychotics, which are primary treatments of SCZ, to prevent relapses or re-emergence of symptoms of SCZ. H
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Is Insulin Resistance Related to Beta-amyloid and Hippocampal Atrophy Independent of Obesity and Diabetes Mellitus
  • 批准号：
    376855
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $7.29万
  • 财政年份：
    2017
  • 负责人：
    Chung Jun Ku
  • 依托单位：
    New York University (New York, NY)
Imaging neurofibrillary tangles in a high-risk population with a lifetime history of depression for Alzheimer's disease
海外基金